Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis

Background and Purpose- The PCSK9 (proprotein convertase subtilisin-kexin type 9) monoclonal antibody evolocumab lowered LDL (low-density lipoprotein) cholesterol by 59% to 0.8 (0.5-1.2) mmol/L and significantly reduced major vascular events in the FOURIER trial (Further Cardiovascular Outcomes Rese...

Celý popis

Podrobná bibliografia

Vydané v:	Stroke (1970) Ročník 51; číslo 5; s. 1546
Hlavní autori:	Giugliano, Robert P, Pedersen, Terje R, Saver, Jeffrey L, Sever, Peter S, Keech, Anthony C, Bohula, Erin A, Murphy, Sabina A, Wasserman, Scott M, Honarpour, Narimon, Wang, Huei, Lira Pineda, Armando, Sabatine, Marc S
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 01.05.2020
Predmet:	peripheral arterial disease C-reactive protein stroke evolocumab proprotein convertase 9
ISSN:	1524-4628, 1524-4628
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!